Seismic Therapeutic
Seismic Therapeutic is a biotechnology company revolutionizing immunology drug discovery and development by integrating machine learning with biologics drug discovery elements such as structural biology, protein engineering, and translational immunology. The company operates a proprietary IMPACT platform to create optimized biologic therapies targeting dysregulated adaptive immunity for autoimmune diseases. With a strong leadership team and scientific founders, Seismic has a growing pipeline of best-in-class and first-in-class biologics, including clinical and preclinical candidates. Their approach emphasizes hyper-collaboration, inclusivity, and patient-centric innovation, positioning them as a leader in the immunology therapeutics space with significant traction in clinical trials and a robust investor syndicate.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company revolutionizing immunology drug discovery and development by integrating machine learning with biologics drug discovery elements such as structural biology, protein engineering, and translational immunology. The company operates a proprietary IMPACT platform to create optimized biologic therapies targeting dysregulated adaptive immunity for autoimmune diseases. With a strong leadership team and scientific founders, Seismic has a growing pipeline of best-in-class and first-in-class biologics, including clinical and preclinical candidates. Their approach emphasizes hyper-collaboration, inclusivity, and patient-centric innovation, positioning them as a leader in the immunology therapeutics space with significant traction in clinical trials and a robust investor syndicate.
TL;DR
Stage: Clinical-stage immunology biotechnology company
Core technology: IMPACT platform — machine learning + structural biology for biologic design
Lead programs: Includes S-1117 (IgG protease) and S-4321 (PD-1 agonist); programs targeting IgE/allergic diseases
Funding: Raised a $121M Series B (Dec 4, 2023); total reported capital $222M
Founders include Jo Viney and Alan Crane; investors include Lightspeed, Bessemer, GV, Polaris, Amgen Ventures and others
